Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.64) per share. This is a 8.57 percent increase over losses of $(0.70) per share from the same period last year.
Benchmark Upgrades Red Robin Gourmet Burgers to Buy, Announces $14 Price Target
Benchmark analyst Todd Brooks upgrades Red Robin Gourmet Burgers (NASDAQ:RRGB) from Hold to Buy and announces $14 price target.